The aim of this study was to develop an efficient method for packaging and concentrating lentiviral vectors that consistently yields high-titer virus on a scale suitable for in vivo applications. Transient co-transfection of 293T packaging cells with DNA plasmids encoding lentiviral vector components was optimized using Superfect, an activated dendrimerbased transfection reagent. The use of Superfect allowed reproducible and efficient production of high-titer lentiviral vector at concentrations greater than 1 x 10 7 transducing units per ml (TU/ml) and required less than one-third of the total amount of DNA used in traditional calcium phosphate transfection methods. Viral titers were further increased using a novel concentration protocol that yielded an average final titer of 1.4 x 10 10 TU/ml. Lentiviruses produced using these methods exhibited efficient transduction of central nervous system and peripheral tissues in vivo. The method is reproducible and can be scaled up to facilitate the use of these vectors in animal studies.
INTRODUCTION
Lentiviral vectors derived from the human immunodeficiency virus type 1 (HIV-1) are emerging as the vectors of choice for long-term, stable in vitro and in vivo gene transfer. These vectors are attractive because they can carry large transgenes (up to 18 kb in size) (13) and they are capable of stably transducing both dividing and quiescent cells (10, 14, 24) .
The increase in interest in these vectors has given rise to a need for efficient and reproducible methods to produce large quantities of high-titer lentiviral vector. Traditionally, lentiviral vectors are produced by co-transfecting human cell lines with plasmid DNA that encodes the viral components required for packaging. Transient transfection of these cell lines is often accomplished using the conventional calcium phosphate co-precipitation technique (15) .
Disadvantages of this method include: (1) the large amount of plasmid DNA that is required for transfection; (2) the difficulties associated with scaling up the precipitation reaction; and (3) the high degree of variability observed in transfection efficiency and viral production. Recently, several groups have developed packaging cell lines that facilitate the production of lentiviral vectors by reducing the need for multi-plasmid transfections (6, 12, 16, 20) . Although the use of packaging cell lines has streamlined the packaging procedure, the resulting viral titers have not been significantly higher than those obtained using transient co-transfection methods. In addition, the advantages of these new cell lines are often offset by the need to develop new lines for each generation of improved lentiviral vector.
To achieve large-scale production of high-titer lentiviral vector it is critical that transfection of the virus-producing cell cultures be both efficient and reproducible; however, little effort has been put forth to optimize this step in vector production. The goal of this study was to develop efficient and reproducible transfection and concentration methods for the production of high titer lentiviral vector stocks. By combining a transfection method that utilizes the activated dendrimer-based transfection reagent, Superfect (Qiagen) with a novel vector concentration protocol, we were able to reproducibly generate lentiviral vector stocks with titers greater than 1 x 10 10 transducing units per ml (TU/ml) using less than one-third of the total amount of plasmid DNA that is commonly required for production of this vector. The viruses produced using these methods exhibit high transduction efficiencies in vivo.
MATERIALS AND METHODS

Lentiviral vector constructs
The transducing vector used in our experiments was derived from a previously described self-inactivating vector (5, 10). The pTY vector was modified by inserting a cPPT-DNA FLAP element upstream of the multiple cloning site, an element that has been shown to significantly improve the transduction efficiency of recombinant lentiviral vectors in vitro and in vivo (8, 23) . A 186-bp fragment containing the cPPT-DNA FLAP sequence was amplified from the pNHP vector using the polymerase chain reaction and the same core primers that have been previously described (22) . Eag1 and Not1 restriction sites were added to the sense and antisense primers, respectively. The resulting fragment was cloned into the Not1 site of the pTY vector in the sense orientation creating the pTYF vector. The integrity of this modification was verified by DNA sequencing. The pTYF vector used in these experiments carries a placental alkaline phosphatase (PLAP) reporter gene (3) driven by the human elongation factor-1α (EF1α) promoter (21) . For some experiments, PLAP was replaced with an enhanced green fluorescent protein (eGFP) reporter gene. Transfection-grade DNA was prepared using endotoxin-free DNA mega-or maxiprep kits (Qiagen).
Lentiviral vector production, concentration and titers
VSV-G-pseudotyped lentiviruses carrying an EF1α-PLAP or EF1α-eGFP transgene were prepared using the lentiviral vector system illustrated in The contents of the tube were gently mixed and incubated at room temperature for 10 min. 
Delivery of EF1α α α α-PLAP vector to chicken neural tube
The neural tube injections and preparation of retinal flat mounts were carried out using previously described methods (4) . The brains of injected embryos were fixed overnight in 4% paraformaldehyde at 4°C. The next day, the tissues were rinsed thoroughly in PBS and 100 µm thick sections were cut using a vibratome. Floating brain sections and retinal flat mounts were subsequently processed for routine PLAP histochemistry as described above. All tissues were collected on embryonic day 7 (E7), 5 days after injections. Digital images of retinal flat mounts were captured with a Nikon Coolpix 995 camera fitted to a Zeiss Stemi V6 microscope. The percent area of retina transduced by the vector was determined as follows: TIFF images at a resolution of 1024 x 768 pixels were reduced by 35%, converted to grayscale using Adobe
Photoshop and imported into the Scion Image program (available at http://www.scioncorp.com).
The density slice setting was used to select all of the pixels within the area of the flat mount that represented PLAP-positive areas and these were expressed as a percent of the total retinal area. Three to seven retinas were analyzed for each dose of vector.
Delivery of EF1α α α α-eGFP vector to brain nuclei
Male Wistar rats were anesthetized with a mixture of ketamine (60 mg/kg) and medetomidine (250 µg/kg) and placed in a stereotaxic frame. Vector delivered to the brain was per group) and 120 (n = 2 per group) days post-injection. Tissues were processed for routine PLAP histochemistry as described above. Digital images were obtained using the methods described above.
RESULTS
Lentivirus production and concentration
The goals of our first series of experiments were to determine the optimum ratio of total plasmid DNA to Superfect reagent that produced the highest titer virus and the optimum time for viral harvest. This ratio was determined to be 1:2 (ratios of 1:1, 1:1. The average overall percent recovery of the virus was 40%. 
In vivo performance of the lentiviral vector
DISCUSSION
By optimizing both the DNA transfection and viral concentration steps for production of lentiviral vector, we have overcome many of the problems that we had previously encountered in our efforts to produce large volumes of high-titer lentiviral vector in a consistent manner. We found that Superfect-mediated transfection of viral packaging cells consistently yielded largescale vector stocks (~120 ml) with starting titers averaging >1.0 x 10 7 TU/ml, titers that were comparable to vector stocks prepared using other transfection reagents. Use of Superfect greatly simplified the transfection protocol and significantly reduced the amount of plasmid DNA required for the procedure. The viral concentration protocol that we developed consistently increased the titers of the viruses by approximately 1000-fold (~1 x 10 10 TU/ml). Furthermore, all vectors that we produced using these methods exhibited high transduction efficiencies in vivo.
Three different in vivo paradigms were used to examine the transduction efficiency of the viral particles produced using this protocol. In the first paradigm, we delivered lentiviral vector into the neural tube of the developing chicken embryo. The injected virus transduced several populations of neural progenitor cells, including those fated to become the neural retina ( Figure   3 ). A majority of cells exposed to virus during this stage of development are mitotic and have not yet differentiated (18) . By varying the concentration of the virus injected, we found that the percent of retina transduced could be controlled in a linear fashion using does between 10 8 and 10 9 TU/ml. Injections of virus at a concentration of 10 10 TU/ml produced maximal levels of retinal transduction. In a previous study, we showed that it is possible to specifically target lentiviral vector-mediated expression of transgenes to retinal photoreceptor cells by selecting appropriate promoter fragments (4). Together, these results illustrate the effectiveness of our vector to transduce cells within the developing nervous system and illustrate the potential use of this vector as a tool for studies of mechanisms regulating gene expression in vivo.
In the second paradigm, lentiviral vector carrying an EF1α-eGFP transgene was injected into specific nuclei within adult rat brain. Analyses of the brains of these animals revealed that we were able to effectively target the virus to cells, including neurons, within the PVN and NTS (Figure 4) . Furthermore, the expression of GFP was robust and persisted for at least 30 days post-injection. Our ability to transduce neurons in brain nuclei involved in cardiovascular homeostasis will allow us to study both the acute and chronic physiological impact of the expression of relevant genes without generating transgenic and/or knockout animals.
Finally, we show that lentiviral vector delivered systemically can transduce several different tissues ( Figure 5 ) and that the transgenes carried by these vectors exhibit long-term expression (120 days, duration of the experiment). Expression of the PLAP reporter gene was highest in the liver and cardiomyocytes. Other organs, such as lung, kidney and adrenal glands were also transduced by the vector, but exhibited only limited PLAP expression. Surprisingly, our studies also showed that the systemically delivered lentiviral vector transduced germ cells in the male rat ( Figure 6 ). To our knowledge, this is the first example of viral vector-mediated germ cell transduction in which transgene expression was detected using histochemical methods rather than PCR-based detection methods (1, 17) . Expression of PLAP was seen within the testicular tubule spermatogonia and included PLAP-positive spermatocyte, spermatid, and mature spermatozoa.
Our observation of transduced germ cells in male rats, while intriguing, must be interpreted with caution with regard to its potential impact on the use of lentiviral vectors for gene therapy. We believe that the transduction we observed could be attributed to the poorly developed blood-testicular barrier that is present in 5-day-old rats (19) . It is our hypothesis that injections of lentivirus after this barrier has matured will not result in transduction of germ cells. It would be interesting to determine if our hypothesis is correct by conducting these experiments in adult animals, an experiment that is now possible using our new viral packaging protocol.
In summary, the transfection and concentration protocols outlined here allow efficient, reproducible production of high-titer lentiviral vectors that exhibit robust transduction properties in vivo. The transfection protocol itself is simple and can be easily implemented by investigators interested in producing lentiviral vector in their laboratories. Furthermore, the methods can be easily adapted to large-scale lentiviral production protocols that are currently being developed for use in large animal studies or for possible use in clinical studies. 
ACKNOWLEDGEMENTS
